Literature DB >> 11544358

Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery.

J W Campbell1, J E Cronan.   

Abstract

The increase in drug-resistant pathogenic bacteria has created an urgent demand for new antibiotics. Among the more attractive targets for the development of new antibacterial compounds are the enzymes of fatty acid biosynthesis. Although a number of potent inhibitors of microbial fatty acid biosynthesis have been discovered, few of these are clinically useful drugs. Several of these fatty acid biosynthesis inhibitors have potential as lead compounds in the development of new antibacterials. This review encompasses the known inhibitors and prospective targets for new antibacterials.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544358     DOI: 10.1146/annurev.micro.55.1.305

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  149 in total

1.  Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery.

Authors:  Hans Peter Fischer; Nina A Brunner; Bernd Wieland; Jesse Paquette; Ludwig Macko; Karl Ziegelbauer; Christoph Freiberg
Journal:  Genome Res       Date:  2004-01       Impact factor: 9.043

Review 2.  Control of membrane lipid fluidity by molecular thermosensors.

Authors:  María C Mansilla; Larisa E Cybulski; Daniela Albanesi; Diego de Mendoza
Journal:  J Bacteriol       Date:  2004-10       Impact factor: 3.490

3.  Antibacterial activity of a triclosan-containing resin composite matrix against three common oral bacteria.

Authors:  Andreas Rathke; Rainer Staude; Rainer Muche; Bernd Haller
Journal:  J Mater Sci Mater Med       Date:  2010-07-17       Impact factor: 3.896

Review 4.  The reductase steps of the type II fatty acid synthase as antimicrobial targets.

Authors:  Yong-Mei Zhang; Ying-Jie Lu; Charles O Rock
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

5.  Biochemical and structural characterization of an essential acyl coenzyme A carboxylase from Mycobacterium tuberculosis.

Authors:  Gabriela Gago; Daniel Kurth; Lautaro Diacovich; Shiou-Chuan Tsai; Hugo Gramajo
Journal:  J Bacteriol       Date:  2006-01       Impact factor: 3.490

6.  In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  James A Karlowsky; Nancy M Laing; Trish Baudry; Nachum Kaplan; David Vaughan; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

7.  Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.

Authors:  Kook-Han Kim; Joon Kyu Park; Byung Hak Ha; Jin Ho Moon; Eunice EunKyeong Kim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-02-28

Review 8.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

9.  Elucidating the structural basis of diphenyl ether derivatives as highly potent enoyl-ACP reductase inhibitors through molecular dynamics simulations and 3D-QSAR study.

Authors:  Pharit Kamsri; Auradee Punkvang; Patchareenart Saparpakorn; Supa Hannongbua; Stephan Irle; Pornpan Pungpo
Journal:  J Mol Model       Date:  2014-06-17       Impact factor: 1.810

10.  Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.

Authors:  Sylvia R Luckner; Carl A Machutta; Peter J Tonge; Caroline Kisker
Journal:  Structure       Date:  2009-07-15       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.